Does interferon beta help in secondary progressive MS?

Neurology

Volumn 63, Issue 10, 2004, Pages 1768-1769

  Cohen, Jeffrey A ^a   Antel, Jack P ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; INTERFERON BETA SERINE;

BRAIN ATROPHY; DISABILITY; DISEASE COURSE; EDITORIAL; HUMAN; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE;

EID: 8844278988     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000147171.32178.48     Document Type: Editorial

References (15)

1. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability, Brain 1989;112:133-146.
2. European Study Group on Interferon b-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
3. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-1504.
4. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon b-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-687.
5. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a three-year controlled study. Neurology 2004;63:1788-1795.
6. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004;63:1779-1787.
7. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997;42:379-382.
8. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998;339:285-291.
9. Kappos L, Mori D, Radu EW, et al. Predictive value of gadolinium-enhanced MRI for relapse rate and in development of disability in multiple sclerosis: a metaanalysis. Lancet 1999;353:964-969.
10. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304.
11. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999;53:751-757.
12. Rice GPA, Filippi M, Comi G, for the Cladribine Clinical Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000;54:1145-1155.
13. Filippi M, Rovaris M, Iannucci G, et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000;55:1714-1718.
14. Leary SM, Thompson AJ. Treatment for patients with primary progressive multiple sclerosis. In: Cohen JA, Rudick RA, eds. Multiple sclerosis therapeutics. London: Martin Dunitz, 2003:589-598.
15. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412-1420.